Read by QxMD icon Read

OncoTargets and Therapy

Shuzhen Liang, Kecheng Xu, Lizhi Niu, Xiaohua Wang, Yingqing Liang, Mingjie Zhang, Jibing Chen, Mao Lin
In the present study, we aimed to compare the clinical outcome of autogeneic and allogeneic natural killer (NK) cells immunotherapy for the treatment of recurrent breast cancer. Between July 2016 and February 2017, 36 patients who met the enrollment criteria were randomly assigned to two groups: autogeneic NK cells immunotherapy group (group I, n=18) and allogeneic NK cells immunotherapy group (group II, n=18). The clinical efficacy, quality of life, immune function, circulating tumor cell (CTC) level, and other related indicators were evaluated...
2017: OncoTargets and Therapy
Da-Xiong Zeng, Chang-Guo Wang, Jian-An Huang, Jun-Hong Jiang
Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer. In this study, we show the result of apatinib as salvage treatment in lung adenocarcinoma patients with KRAS mutation. Four advanced lung adenocarcinoma patients with KRAS mutation were orally administered apatinib (250 mg/d) after second-line treatment...
2017: OncoTargets and Therapy
Ling Peng, Yina Wang, Yemin Tang, Lei Zeng, Junfang Liu, Zhu Zeng, Jian Liu, Peng Shi, Xianghua Ye, Qiong Zhao
BACKGROUND: Several clinical studies have demonstrated that continuous administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could provide additional survival benefit for advanced non-small cell lung cancer (NSCLC) patients who had benefited from prior EGFR TKI therapy. However, whether EGFR TKI combined with chemotherapy could further prolong survival in patients with gradual progression is still unclear. The present study was conducted to evaluate the clinical outcome of continuous EGFR TKI treatment in combination with chemotherapy (combination group) versus continuous EGFR TKI treatment only (monotherapy group) in such a clinical setting...
2017: OncoTargets and Therapy
Jin Wang, Xiaoyang Liu, Changsheng Yan, Jie Liu, Songtao Wang, Yongzhi Hong, Aihua Gu, Peng Zhao
OBJECTIVES: The long-noncoding RNAs (lncRNAs) are identified as new crucial regulators of diverse cellular processes in glioblastoma (GBM) tissues. However, the expression pattern and biological function of lncRNAs remain largely unknown. Here, for the first time, the effects of lncRNA lymphoid enhancer-binding factor 1 antisense RNA 1 (LEF1-AS1) on GBM progression both in vitro and in vivo are investigated. MATERIALS AND METHODS: Expression profiles of LEF1-AS1 in GBM specimens were investigated by bioinformatics analyses...
2017: OncoTargets and Therapy
Ovidiu-Leonard Braicu, Liviuta Budisan, Rares Buiga, Ancuta Jurj, Patriciu Achimas-Cadariu, Laura Ancuta Pop, Cornelia Braicu, Alexandru Irimie, Ioana Berindan-Neagoe
Endometriosis is an inflammatory pathology associated with a negative effect on life quality. Recently, this pathology was connected to ovarian cancer, in particular with endometrioid ovarian cancer. microRNAs (miRNAs) are a class of RNA transcripts ~19-22 nucleotides in length, the altered miRNA pattern being connected to pathological status. miRNAs are highly stable transcripts, and these can be assessed from formalin-fixed paraffin-embedded (FFPE) samples leading to the identification of miRNAs that could be developed as diagnostic and prognostic biomarkers, in particular those involved in malignant transformation...
2017: OncoTargets and Therapy
Xiao-Yan Zhang, Xiao-Ting Li, Jia Sun, Ying-Shi Sun
PURPOSE: To determine the correlation between continuously distributed diffusion-weighted image (DWI)-derived parameters and histopathologic indexes. METHODS: Fifty-four mice bearing HCT-116 colorectal tumors were included for analysis; 12 mice were used for continuous observation, and the other 42 mice were used for break-point observation. All mice were randomly divided into radiotherapy and non-radiotherapy groups. Optical imaging and MRI were performed at different time points according to radiotherapy regimen (baseline, 24 h, 48 h, 72 h, 7 d, 14 d, and 28 d)...
2017: OncoTargets and Therapy
Shan Cao, Jingxia Sun, Shuai Lin, Lu Zhao, Di Wu, Tian Liang, Wenji Sheng
BACKGROUND: The aim of this study was to explore the relationships of HPIP expression status with the clinicopathological variables and survival outcomes of patients with cervical cancer (CC). METHODS: We compared the HPIP expression of 119 samples from CC tissues, 20 from cervical intraepithelial tissues, and 20 from normal cervical tissues by using immunohistochemical staining. RESULTS: It was observed that the ratio of elevated HPIP expression was higher in CC tissues than in cervical intraepithelial neoplasia (P=0...
2017: OncoTargets and Therapy
Yucai Zhang, Xiaorui Zhang, Anqi Zhang, Ke Li, Kai Qu
PURPOSE: This study aimed to systematically evaluate the efficacy and safety of dendritic cells-cytokine-induced killer (DC-CIK) cells immunotherapy in treating pancreatic cancer (PC) patients. METHODS: Data were collected from published articles of clinical trials. Databases including Web of Science, EMBASE, PubMed, Cochrane Library, Wanfang, and CNKI were searched. The main outcome measures in this research included the overall response rate (ORR), disease control rate (DCR), overall survival (OS), patients' quality of life (QoL), immune function, and adverse events...
2017: OncoTargets and Therapy
Min Ma, Shilin Chen, Zhuo Liu, Hailong Xie, Hongyu Deng, Song Shang, Xiaohong Wang, Man Xia, Chaohui Zuo
Worldwide, gastric cancer (GC) is one of the deadliest malignant tumors of the digestive system. Moreover, microRNAs (miRNAs) of exosomes harbored within cancer cells have been determined to induce inflammatory conditions that accelerate tumor growth and metastasis. Interestingly, the oncogenic role of bone marrow mesenchymal stem cells (BM-MSCs) in the modulation of immunosuppression, tumor invasion, and metastasis was discovered to be partly mediated through the secretion of exosomes. In this article, high expression of miRNA-221 (miR-221) in exosomes of the peripheral blood was determined to be positively correlated with the poor clinical prognosis of GC, especially with respect to tumor, node, and metastases stage...
2017: OncoTargets and Therapy
Dakeun Lee, Eun Ji Yu, In-Hye Ham, Hoon Hur, You-Sun Kim
BACKGROUND: The At-rich interactive domain 1A (ARID1A) is frequently mutated in gastric cancers (GCs) with a poor prognosis. Growing evidence indicates that loss of ARID1A expression leads to activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway by AKT phosphorylation. We aim to investigate the different sensitivity for the AKT inhibitor in ARID1A-deficient GC cells. METHODS: After transfection using siRNA or shRNA, the effect of ARID1A knockdown on the PI3K/AKT signaling pathway was evaluated by Western blot analysis...
2017: OncoTargets and Therapy
Fang Liu, Ming Gong, Li Gao, Xiaoping Cai, Hui Zhang, Yigai Ma
OBJECTIVE: The purpose of this study was to evaluate the frequency of RASSF1A hypermethylation in patients with acute myeloid leukemia (AML), in an attempt to modify the current molecular model for disease prognosis. MATERIALS AND METHODS: Aberrant RASSF1A promoter methylation levels were assessed in 226 newly diagnosed non-M3 AML patients and 30 apparently healthy controls, by quantitative methylation-specific polymerase chain reaction. Meanwhile, RASSF1A mRNA levels were detected by real-time quantitative polymerase chain reaction...
2017: OncoTargets and Therapy
Hisashi Saji, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Haruhiko Nakamura
OBJECTIVE: We previously reported that the staging system and epidermal growth factor receptor (EGFR) mutation status are key factors for treatment strategy and predicting survival. However, the significance of these factors as predictors of overall survival (OS) and postoperative recurrence survival (PRS) has not been sufficiently elucidated. The objective here was to investigate EGFR mutation status and p-stage, which affect PRS and OS in patients with completely resected lung adenocarcinoma, using a different database...
2017: OncoTargets and Therapy
Zheng Zhao, Zhangjun Song, Xuwei Wang, Haifeng Sun, Xiaomin Yang, Yong Yuan, Pan Yu
ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal...
2017: OncoTargets and Therapy
Ming Gu, Xinyu Zheng
INTRODUCTION: Osteopontin (OPN), a multifunctional phosphoprotein, has been implicated in a series of important physiologic and pathophysiologic processes. In breast cancer, OPN functionally contributes to the tumorigenicity of spheroid-forming cells. It also plays a critical role in enhancing the proliferation, tumorigenicity, and ability to display vasculogenic mimicry (VM) of spheroid-forming cells in breast cancer. However, the role of OPN in breast cancer is not clear. PATIENTS AND METHODS: This study investigated OPN expression and VM in breast cancer patients before neoadjuvant chemotherapy (NACT)...
2017: OncoTargets and Therapy
Yong-Fa Chen, Wu-Bin Tang, Xin-Xi Pan, Chu-Rong Wu, Yang Cao, Wen Yang
OBJECTIVE: To evaluate efficacy and safety of nimotuzumab combined with chemotherapy and radiotherapy in women with locally advanced cervical cancer. MATERIALS AND METHODS: Women with locally advanced cervical cancer (stage IIB, III, or IVA) who experienced relapse after first-line chemoradiotherapy and one or more lines of palliative chemotherapy were enrolled. All patients received nimotuzumab weekly at 200 mg/m(2) as single agent for 4 weeks (induction phase), then concurrent with 6 cycles (21-day per cycle) of gemcitabine (800 mg/m(2)) or cisplatin (50 mg/m(2)) for 18 weeks (concurrent phase) and then once every 2 weeks (maintenance phase)...
2017: OncoTargets and Therapy
Wenlong Zhong, Rongcheng Lin, Lei Zhang, Chengyue Jin, Xuesong Li, Qun He, Kan Gong, Zhisong He, Liqun Zhou
PURPOSE: The aim of this case series was to review the standard diagnosis and treatment procedures of primary small cell carcinoma (SCC) in our institution and discuss the clinicopathologic characteristics, treatments and outcomes of patients with primary ureteral SCC. PATIENTS AND METHODS: Patients diagnosed with ureteral SCC in Peking University First Hospital, Beijing, China, from January 2007 to December 2016 were included. In addition, we performed a systematic literature review, in October 2016, on case reports and case series of ureteral SCC...
2017: OncoTargets and Therapy
Joanna Lipińska, Leszek Kutwin, Marcin Wawrzycki, Leszek Olbrzymek, Sławomir Jabłoński
INTRODUCTION: Resection of manubrium or body of the sternum is associated with a necessity of chest wall reconstruction. Large sternal defects require the use of different types of implants to ensure acceptable esthetic effect for the patient and chest stabilization. AIM: The purpose of this case report is to present a novel method of reconstruction of manubrium removed due to renal cancer metastasis to the sternum. CASE: We present the case of a patient, who had underwent right nephrectomy for clear cell kidney cancer, diagnosed with a metastatic tumor in the sternum resulting in destruction of manubrium...
2017: OncoTargets and Therapy
Sheel A Patel, Jean Hoffman-Censits
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for this disease state. The optimal sequencing of these agents is unclear as there are no large-scale head-to-head comparisons. Clinicians must familiarize themselves with the most recent studies as well as drug toxicities to determine the best treatment option for their patients...
2017: OncoTargets and Therapy
Lina Tong, Ping Liu, Bin Huo, Zhi Guo, Hong Ni
OBJECTIVE: This retrospective study aimed to evaluate the feasibility, safety, and clinical efficacy of computed tomography (CT)-guided (125)I seed interstitial brachytherapy for pelvic recurrent cervical cancer in patients with a history of pelvic radiotherapy. METHODS: From March 2011 to December 2015, 35 pelvic recurrent lesions (33 patients) were reirradiated using this type of salvage therapy. The medical history, dose-volume histogram parameters, complications, local control, overall survival (OS), and affected factors were analyzed...
2017: OncoTargets and Therapy
Yafei Wang, Hong Su, Yuanliang Gu, Xin Song, Jinshun Zhao
Chromium has two main valence states: hexavalent chromium (Cr[VI]) and trivalent chromium (Cr[III]). Cr(VI), a well-established human carcinogen, can enter cells by way of a sulfate/phosphate anion-transport system, and then be reduced to lower-valence intermediates consisting of pentavalent chromium (Cr[V]), tetravalent chromium (Cr[IV]) or Cr(III) via cellular reductants. These intermediates may directly or indirectly result in DNA damage or DNA-protein cross-links. Although Cr(III) complexes cannot pass easily through cell membranes, they have the ability to accumulate around cells to induce cell-surface morphological alteration and result in cell-membrane lipid injuries via disruption of cellular functions and integrity, and finally to cause DNA damage...
2017: OncoTargets and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"